Fedovapagon is in clinical development as an oral treatment for nocturia in men with benign prostate enlargement. Nocturia is a common symptom in men who have enlarged prostates. Nocturia is generally defined as excessive or disruptive (either due to the volume of urine or frequency of trips to the toilet) night-time urination which disrupts sleep and impairs quality of life. There are currently no specific treatments for nocturia in men with enlarged prostates. Instead, nocturia is currently managed with drugs prescribed to treat the general symptoms of enlarged prostates, which are rarely effective in treating nocturia and can have side effects. As this is a common symptom in men with this condition, there is a clinical need for this type of treatment.
Fedovapagon works directly in the collecting ducts of the kidney by binding to, and activating receptors that causes the kidneys to reabsorb water from urine as it passes towards the bladder. If fedovapagon is administered before going to bed the result is less urine produced overnight. Therefore, if licensed, fedovapagon would be the first medicinal product specifically for the treatment of nocturia in men with enlarged prostates.
The Human acellular vessel (HAV) is in clinical development to provide vascular access for haemodialysis patients with end-stage renal disease (ESRD). ESRD is a long-term irreversible condition where the kidneys do not work as well as they should as a result of chronic kidney disease. There is no cure for kidney failure and patients with this condition requires haemodialysis or a renal transplant for survival. Haemodialysis works by taking blood from the body and cleaning it through a machine to remove the toxins. Blood is filtered before being returned to the body. Vascular access is a way to reach the blood during haemodialysis.